Search Results for 'nscl'
nscl published presentations and documents on DocSlides.
Antiangiogenic Agents in Advanced NSCLC
by ellena-manuel
Jared Weiss, MD . Assistant . Professor of Medici...
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
by stefany-barnette
Renato G. Martins, MD, MPH. Medical Director, Tho...
NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti
by sawyer742
Intervista a Federico . Cappuzzo. Background:. Pr...
SW GLH services for NSCLC – An update
by everly
Professor Rachel Butler. The genomic complexity of...
EGFR-Mutated Advanced NSCLC
by sherrill-nordquist
The Coming Paradigm Shift. Faculty. Suresh S. Ram...
Raising the Bar in the Management of Advanced/Metastatic NSCLC
by debby-jeon
Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...
NSCLC: Epidemiology and disease characteristics
by scarlett
NSCLC, non-small cell lung cancer.. Lung cancer in...
Treatment in Advanced Non-Small Cell Lung Cancer
by oconnor
. 5. th. most commonly diagnosed cancer in Austra...
Multidisciplinary approach to lung cancer
by elena
Kamil Konopka. Department of Oncology, University ...
Beth Sandy, MSN, CRNP Nurse Practitioner
by PriceOfFreedom
Abramson Cancer Center . University of Pennsylvani...
Please note, these are the actual video-recorded
by chaptoe
proceedings from the live CME event and may includ...
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
by southan
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pra...
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature
by stefany-barnette
The Cancer genome atlas (TCGA) and the search for...
The Role of Antiangiogenic Agents
by luanne-stotts
The Role of Antiangiogenic Agents in the Changin...
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
by pasty-toler
This program will include a discussion of off-lab...
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
Using Non-targeted Therapies in Targeted Lung Cancer Popula
by ellena-manuel
Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...
Working Group on Central Nuclear Reactions/EOS
by giovanna-bartolotta
Pawel Danielewicz (NSCL/MSU). Justin Estee (NSCL/...
NSCLC with high PD-L1 expression on tumor cells or tumor-in
by test
Intervista a Federico . Cappuzzo. Background:. P...
Preliminaries https://people.nscl.msu.edu/~witek/Classes/PHY802/NuclPhys802-2015.
by scarlett
html. Instructor: Witold Nazarewicz and guest star...
ALK in lung cancer: Past, present, and future
by belinda
Gene Mutations in Lung . Adenocarcinomas. 17 years...
AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie
by susan2
DisclosureStatement:Theauthorhasnothingtodisclose....
NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM
by cecilia
NCCNCATEGORIESOFEVIDENCEANDCONSENSUSCategory1:Base...
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
by adia
RecommendationLoE, GoRScreening with LDCT (low-dos...
ALL, Acute lymphoblastic leukemia;
by HappyHippo
BCMA, B-cell maturation antigen; DLBCL, diffuse la...
iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung
by berey
Interview with Shirish M . Gadgeel. , MD . January...
Mechanisms of ALK Resistance & Implications for Treatment
by evans
Robert C. Doebele, MD, PhD. Associate Professor, ....
Targeting KRAS G12C Â in Solid Tumors
by morton
: . A . New Anticancer Approach  . Marwan Fakih, ...
NSCLC: Staging and TNM classification
by molly
NSCLC, non-small cell lung cancer; TNM. , tumour, ...